SubsidieMeestersA revolutionary technology platform for providing life-saving treatment for end-stage heart failure patients
reBEAT is an innovative heart support technology that safely assists both sides of the heart, aiming to improve treatment accessibility and cost-effectiveness for end-stage heart failure patients.
Projectdetails
Introduction
Over 500K patients in the EU and US suffer from end-stage heart failure (HF), with a life expectancy of <1 year in 38% of cases. The prevalence of HF has increased recently, mainly due to improved survival after heart attacks. Such patients require mechanical support of their hearts.
Current Treatment Options
Available treatment options are:
- Heart transplantation (HTX)
- Ventricular assist device (VAD)
Today, <3% of these patients are treated due to donor heart shortages and restrictive employment of VADs.
Limitations of Existing Solutions
VADs can cause severe complications, such as:
- Bleeding
- Strokes
Additionally, VADs typically only support one side of the heart.
reBEAT Technology
reBEAT is a revolutionary technology to mechanically support both sides of the heart. It has several advantages:
- Does not directly contact blood
- Can be easily implanted (~40 minutes)
- Presents virtually no contraindications for the patient population described
Cost Effectiveness and Revenue Expectations
reBEAT offers high cost effectiveness at <50% of the cost of heart transplantations and VADs. AdjuCor expects revenues of 69M€ by 2027 with reBEAT.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.499.999 |
| Totale projectbegroting | € 3.912.949 |
Tijdlijn
| Startdatum | 1-1-2023 |
| Einddatum | 31-12-2024 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- ADJUCOR GMBHpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
A new cardioprotective drug for acute treatment of myocardial infarctionResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Clear, scalable and scientific framework to measure terrestrial biodiversity3Bee leverages IoT, wildlife monitoring, and satellite data to measure and regenerate biodiversity, generating certified Biodiversity Credits for corporations to enhance ESG reporting and brand value. | EIC Accelerator | € 2.252.714 | 2024 | Details |
Novel and Scalable microbial products for REgenerative agricultureN-Spire aims to revolutionize agriculture by creating a sustainable bioactive fertilizer through innovative manufacturing techniques, enhancing soil health and reducing chemical dependency. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Quantum-based Randomness Processing Units (RPUs) for High-Performance Computation and Data SecurityQuside's Randomness Processing Unit (RPU) accelerates stochastic HPC and PQ cryptography by optimizing random workloads, enhancing efficiency and performance across various sectors. | EIC Accelerator | € 2.499.999 | 2024 | Details |
A new cardioprotective drug for acute treatment of myocardial infarction
ResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies.
Clear, scalable and scientific framework to measure terrestrial biodiversity
3Bee leverages IoT, wildlife monitoring, and satellite data to measure and regenerate biodiversity, generating certified Biodiversity Credits for corporations to enhance ESG reporting and brand value.
Novel and Scalable microbial products for REgenerative agriculture
N-Spire aims to revolutionize agriculture by creating a sustainable bioactive fertilizer through innovative manufacturing techniques, enhancing soil health and reducing chemical dependency.
Quantum-based Randomness Processing Units (RPUs) for High-Performance Computation and Data Security
Quside's Randomness Processing Unit (RPU) accelerates stochastic HPC and PQ cryptography by optimizing random workloads, enhancing efficiency and performance across various sectors.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Technology Of Protein delivery in Extracellular Vesicle-induced Cardiac RepairTOP-EVICARE aims to enhance cardiac repair in heart failure by developing innovative protein loading systems in extracellular vesicles, ensuring effective delivery and commercialization. | ERC POC | € 150.000 | 2023 | Details |
SPARK - Subcutaneous Pump and Advanced Remote KitRT Cardiac Systems ontwikkelt een innovatief percutaan mechanisch circulatieondersteuningsapparaat en een subcutane sensor om patiënten met gevorderd hartfalen beter te ondersteunen tijdens noodsituaties en ingrepen. | MIT R&D Samenwerking | € 199.138 | 2023 | Details |
CLOBT: Cardiale Levensreddende Ondersteuning Booster TechnoCardiacBooster heeft een innovatief apparaat ontwikkeld dat het hart van binnenuit ondersteunt, met betere resultaten en minder risico's dan bestaande mechanische ondersteuningssystemen voor cardiogene shockpatiënten. | MIT R&D Samenwerking | € 155.376 | 2020 | Details |
SPARK - Subcutaneous Pump and Advanced Remote KitHet project ontwikkelt een innovatief hartondersteuningssysteem met een subcutane sensor voor betere behandeling van gevorderd hartfalen. | MIT R&D Samenwerking | € 199.138 | 2023 | Details |
Technology Of Protein delivery in Extracellular Vesicle-induced Cardiac Repair
TOP-EVICARE aims to enhance cardiac repair in heart failure by developing innovative protein loading systems in extracellular vesicles, ensuring effective delivery and commercialization.
SPARK - Subcutaneous Pump and Advanced Remote Kit
RT Cardiac Systems ontwikkelt een innovatief percutaan mechanisch circulatieondersteuningsapparaat en een subcutane sensor om patiënten met gevorderd hartfalen beter te ondersteunen tijdens noodsituaties en ingrepen.
CLOBT: Cardiale Levensreddende Ondersteuning Booster Techno
CardiacBooster heeft een innovatief apparaat ontwikkeld dat het hart van binnenuit ondersteunt, met betere resultaten en minder risico's dan bestaande mechanische ondersteuningssystemen voor cardiogene shockpatiënten.
SPARK - Subcutaneous Pump and Advanced Remote Kit
Het project ontwikkelt een innovatief hartondersteuningssysteem met een subcutane sensor voor betere behandeling van gevorderd hartfalen.